A 59-year old gentleman with transformation of myelodysplastic syndrome to acute megakaryoblastic leukemia was treated with standard intensive chemotherapy. His poor outcome was attributed to advanced age, aggressive disease biology, underlying myelodysplastic syndrome, poor response to induction chemotherapy, high lactate dehydrogenase and lack of good cytogenetic and molecular mutations.